The value of dasatinib in the treatment of primary myelofibrosis

The efficiency and side-effect of dasatinib in the treatment of primary myelofibrosis.

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-IIh-16008649

Enrollment

Unknown

Registered

2016-06-15

Start date

2014-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary myelofibrosis

Interventions

Treatment group:Dasatinib

Eligibility

Sex/Gender

All

Age

55 Years to 69 Years

Inclusion criteria

Inclusion criteria: Patients with primary myelofibrosis. All patients joined this study with informed consents.

Exclusion criteria

Exclusion criteria: The patients who withdraw the informed consent form.

Design outcomes

Primary

Measure	Time frame
Spleen;complete blood count;	—

Countries

China

Contacts

Public ContactSong Qinglin

The Peoples' Hospital of Jiaozuo City

hnjzsql@163.com+86 13939183208

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026